|
1
|
Bataille V, Winnett A, Sasieni P, Newton
Bishop JA and Cuzick J: Exposure to the sun and sunbeds and the
risk of cutaneous melanoma in the UK: a case-control study. Eur J
Cancer. 40:429–435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D,
Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N,
Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M,
Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon
DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA and
Chin L: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thomas NE, Berwick M and Cordeiro-Stone M:
Could BRAF mutations in melanocytic lesions arise from DNA damage
induced by ultraviolet radiation? J Invest Dermatol. 126:1693–1696.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas NE, Edmiston SN, Alexander A,
Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg
CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J and
Conway K: Number of nevi and early-life ambient UV exposure are
associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers
Prev. 16:991–997. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Venesio T, Chiorino G, Balsamo A, Zaccagna
A, Petti C, Scatolini M, Pisacane A, Sarotto I, Picciotto F and
Risio M: In melanocytic lesions the fraction of
BRAFV600Ealleles is associated with sun exposure but
unrelated to ERK phosphorylation. Mod Pathol. 21:716–726.
2008.PubMed/NCBI
|
|
6
|
Candido S, Rapisarda V, Marconi A,
Malaponte G, Bevelacqua V, Gangemi P, Scalisi A, McCubrey JA,
Maestro R, Spandidos DA, Fenga C and Libra M: Analysis of the
B-RAFV600Emutation in cutaneous melanoma patients
with occupational sun exposure. Oncol Rep. 31:1079–1082. 2014.
|
|
7
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes
J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S,
Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley
J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G,
Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson
A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL,
Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and
Futreal PA: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Libra M, Malaponte G, Navolanic PM,
Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino
MC, Travali S and McCubrey JA: Analysis of BRAF mutation in primary
and metastatic melanoma. Cell Cycle. 4:1382–1384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ascierto PA, Kirkwood JM, Grob J, Simeone
E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM and
Mozzillo N: The role of BRAF V600 mutation in melanoma. J Transl
Med. 10:852012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen B, Tardell C, Higgins B, Packman K,
Boylan JF and Niu H: BRAFV600E negatively regulates the AKT pathway
in melanoma cell lines. PLoS One. 7:e425982012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vredeveld LC, Possik PA, Smit MA, Meissl
K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D,
McMahon M, Mooi WJ and Peeper DS: Abrogation of BRAFV600E-induced
senescence by PI3K pathway activation contributes to
melanomagenesis. Genes Dev. 26:1055–1069. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lipkin G: Plasticity of the cancer cell:
implications for epigenetic control of melanoma and other
malignancies. J Invest Dermatol. 128:2152–2155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Villanueva J, Adina V, Lee JT,
Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu
X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K,
Pushparajan A, Hayden JE, Kimberly BD, Laquerre S, McArthur GA,
Sosman JA, Nathanson KL and Herlyn M: Acquired resistance to BRAF
inhibitors mediated by a RAF kinase switch in melanoma can be
overcome by co-targeting MEK and IGF-1R/PI3K. Cancer Cell.
18:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Viola JR, Rafael DF, Wagner E, Besch R and
Hindawi MO: Gene therapy for advanced melanoma: selective targeting
and therapeutic nucleic acids. J Drug Deliv. 2013:8973482013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karasarides M, Chiloeches A, Hayward R,
Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D,
Martin J, Marshall CJ, Springer CJ and Marais R: B-RAF is a
therapeutic target in melanoma. Oncogene. 23:6292–6298. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y,
Shujath J, Gawlak S, Eveleigh D, Rowley BL, Adnane L, Lynch M,
Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE,
Bollag G and Trail PA: BAY 43-9006 exhibits broad spectrum oral
antitumor activity and targets the RAF/MEK/ERK pathway and receptor
tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strumberg D, Awada A, Piccart P, Hirte H,
Moore M, Clark J, Lenz HJ, Lathia C, Schwartz B and Humphrey R:
Final report of the phase I clinical program of the novel raf
kinase inhibitor BAY 43-9006 in patients with refractory solid
tumors. J Clin Oncol. 22:2032003.
|
|
20
|
Strumberg D: Preclinical and clinical
development of the oral multikinase inhibitor sorafenib in cancer
treatment. Drugs Today. 41:773–784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Awada A, Hendlisz A, Gil T, Bartholomeus
S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG,
Schwartz B and Piccart M: Phase I safety and pharmacokinetics of
BAY 43-9006 administered for 21 days on/7 days off in patients with
advanced, refractory solid tumours. Br J Cancer. 92:1855–1861.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisen T, Ahmad T, Flaherty KT, Gore M,
Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM,
Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M,
O’Dwyer PJ and Ratain MJ: Sorafenib in advanced melanoma: a Phase
II randomised discontinuation trial analysis. Br J Cancer.
95:581–586. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chakraborty R, Wieland CN and Comfere N:
Molecular targeted therapies in metastatic melanoma. Pharmgenomics
Pers Med. 6:49–56. 2013.PubMed/NCBI
|
|
24
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte
G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S,
Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C,
Chiarini F and Martelli AM: Mutations and deregulation of
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy
response. Oncotarget. 3:954–987. 2012.PubMed/NCBI
|
|
25
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J,
Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F,
Evangelisti C, Cocco L and Martelli AM: Ras/Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in
therapy resistance and how to overcome resistance. Oncotarget.
3:1068–1111. 2012.PubMed/NCBI
|
|
26
|
Pecuchet N, Lebbe C, Mir O, Billemont B,
Blanchet B, Franck N, Viguier M, Coriat R, Tod M, Avril MF and
Goldwasser F: Sorafenib in advanced melanoma: a critical role for
pharmacokinetics? Br J Cancer. 107:455–461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisen T, Marais R, Affolter A, Lorigan P,
Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD,
Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I,
James MG, Strauss UP, Prendergast S and Gore ME: Sorafenib and
dacarbazine as first-line therapy for advanced melanoma: phase I
and open-label phase II studies. Br J Cancer. 105:353–359. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H,
Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L,
Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J,
Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R,
Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B,
Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M and
Bollag G: Discovery of a selective inhibitor of oncogenic B-Raf
kinase with potent antimelanoma activity. Proc Natl Acad Sci USA.
105:3041–3046. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jang S and Atkins MB: Which drug, and
when, for patients with BRAF-mutant melanoma? Lancet Oncol.
14:60–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M,
Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day
SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J,
Nelson B, Hou J, Lee RJ, Flaherty KT and McArthur GA: Improved
survival with vemurafenib in melanoma with BRAF V600E mutation. N
Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Joseph EW, Pratilas CA, Poulikakos PI,
Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A,
Tsai J, Chapman PB, Bollag G, Solit DB and Rosen N: The RAF
inhibitor PLX4032 inhibits ERK signaling and tumor cell
proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci
USA. 107:14903–14908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bollag G, Hirth P, Tsai J, Zhang J,
Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA,
Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen
H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R,
D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov
I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty
KT, Xu X, Nathanson KL and Nolop K: Clinical efficacy of a RAF
inhibitor needs broad target blockade in BRAF-mutant melanoma.
Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD,
Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop
KB, Lee RJ, Joe AK and Ribas A: Survival in BRAF V600-mutant
advanced melanoma treated with vemurafenib. N Engl J Med.
366:707–714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oberholzer PA, Kee D, Dziunycz P, Sucker
A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo
E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA,
Schadendorf D and Garraway LA: RAS mutations are associated with
the development of cutaneous squamous cell tumors in patients
treated with RAF inhibitors. J Clin Oncol. 30:316–321. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Su F, Viros A, Milagre C, Trunzer K,
Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT,
Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H,
Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I,
Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S,
Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx
M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL,
Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ,
McArthur GA, Sosman JA, Lo RS, Ribas A and Marais R: RAS mutations
in cutaneous squamous-cell carcinomas in patients treated with BRAF
inhibitors. N Engl J Med. 366:207–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Corcoran RB, Settleman J and Engelman JA:
Potential therapeutic strategies to overcome acquired resistance to
BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget.
2:336–346. 2011.PubMed/NCBI
|
|
38
|
McCubrey JA, Steelman LS, Kempf CR,
Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra
M, Basecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G,
Cervello M, Cocco L and Martelli AM: Therapeutic resistance
resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR
signaling pathways. J Cell Physiol. 226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shao Y and Aplin AE: Akt3-mediated
resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer
Res. 70:6670–6681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Emery CM, Vijayendrana KG, Zipserc MC,
Sawyera AM, Niua L, Kima JJ, Hattona C, Choprad R, Oberholzera PA,
Karpovac MB, MacConailla LE, Zhangf J, Grayf NS, Sellersd WR,
Dummerc R and Garrawaya LA: MEK1 mutations confer resistance to MEK
and B-RAF inhibition. Proc Natl Acad Sci USA. 106:20411–20416.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Greger JG, Eastman SD, Zhang V, Bleam MR,
Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L and
Gilmer TM: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors
overcome acquired resistance to the BRAF inhibitor GSK2118436
dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther.
11:909–920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Aplin AE, Kaplan FM and Shao Y: Mechanisms
of resistance to RAF inhibitors in melanoma. J Invest Dermatol.
131:1817–1820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Trunzer K, Pavlick AC, Schuchter L,
Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim
KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK,
Lewis KD, Puzanov I, Lo Roger S, Koehler A, Kockx M, Spleiss O,
Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK,
Sosman JA and Ribas A: Pharmacodynamic effects and mechanisms of
resistance to vemurafenib in patients with metastatic melanoma. J
Clin Oncol. 31:1767–1774. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hauschild A, Grob J, Demidov LV, Jouary T,
Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C,
Chiarion-Sileni V, Martin A, Swann S, Haney P, Mirakhur B, Guckert
ME, Goodman V and Chapman PB: Dabrafenib in BRAF-mutated metastatic
melanoma: a multicentre, open-label, phase 3 randomised controlled
trial. Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Long GV, Trefzer U, Davies MA, Kefford RF,
Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi
A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S,
Martin A, Guckert M, Goodman V, Streit M, Kirkwood JM and
Schadendorf D: Dabrafenib in patients with Val600Glu or Val600Lys
BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a
multicentre, open-label, phase 2 trial. Lancet Oncol. 13:1087–1095.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ascierto PA, Minor D, Ribas A, Lebbe C,
O’Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob J,
Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin
A, Mazumdar J, Goodman VL and Trefzer U: Phase II trial (BREAK-2)
of the BRAF inhibitor dabrafenib (GSK2118436) in patients with
metastatic melanoma. J Clin Oncol. 31:3205–3211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Falchook GS, Long GV, Kurzrock R, Kim KB,
Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC,
O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D and
Kefford RF: Dabrafenib in patients with melanoma, untreated brain
metastases, and other solid tumours: a phase 1 dose-escalation
trial. Lancet. 379:1893–1901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Trefzer U, Minor D, Ribas A, Lebbe C,
Siegfried A, Arya N, Guckert M, Schadendorf D, Kefford R, Grob JJ,
Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim K, Goodman V and
Ascierto PA: BREAK-2: a Phase IIA trial of the selective BRAF
kinase inhibitor GSK2118436 in patients with BRAF mutation-positive
(V600E/K) metastatic melanoma. Pigm Cell Melanoma R.
24:10202011.
|
|
49
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar
|
|
50
|
Johnson DB and Sosman JA: Update on the
targeted therapy of melanoma. Curr Treat Options Oncol. 14:280–292.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Thompson N and Lyons J: Recent progress in
targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug
discovery. Curr Opin Pharmacol. 5:350–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Catalanotti F, Solit DB, Pulitzer MP,
Berger MF, Scott SN, Iyriboz T, Lacouture ME, Panageas KS, Wolchok
JD, Carvajal RD, Schwartz GK, Rosen N and Chapman PB: Phase II
trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in
patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res.
19:2257–2264. 2013. View Article : Google Scholar
|
|
54
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P,
Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M,
Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D,
Martin AM, Patel K and Schadendorf D: Improved survival with MEK
inhibition in BRAF-mutated melanoma. N Engl J Med. 367:107–114.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Byron SA, Loch DC, Wellens CL, Wortmann A,
Wu J, Wang J, Nomoto K and Pollock PM: Sensitivity to the MEK
inhibitor E6201 in melanoma cells is associated with mutant BRAF
and wildtype PTEN status. Mol Cancer. 11:752012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Falchook GS, Lewis KD, Infante JR, Gordon
MS, Vogelzang NJ, De Marini DJ, Sun P, Moy C, Szabo SA, Roadcap LT,
Peddareddigari VG, Lebowitz PF, Le NT, Burris HA III, Messersmith
WA, O’Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R,
Kurzrock R and Fecher LA: Activity of the oral MEK inhibitor
trametinib in patients with advanced melanoma: a phase 1
dose-escalation trial. Lancet Oncol. 13:782–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yamaguchi T, Kakefuda R, Tajima N, Sowa Y
and Sakai T: Antitumor activities of JTP-74057 (GSK1120212), a
novel MEK1/2 inhibitor, on colorectal cancer cell lines in
vitro and in vivo. Int J Oncol. 39:23–31.
2011.PubMed/NCBI
|
|
58
|
Gilmartin AG, Bleam MR, Groy A, Moss KG,
Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang
J, Zappacosta F, Annan R, Sutton D and Laquerre SG: GSK1120212
(JTP-74057) is an inhibitor of MEK activity and activation with
favorable pharmacokinetic properties for sustained in vivo pathway
inhibition. Clin Cancer Res. 17:989–1000. 2011. View Article : Google Scholar
|
|
59
|
Akinleye A, Furqan M, Mukhi N, Ravella P
and Liu D: MEK and the inhibitors: from bench to bedside. J Hematol
Oncol. 6:272013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Robert C, Flaherty KT, Hersey P, Nathan P,
Garbe C, Milhem MM, Demidov LV, Hassel JC, Rutkowski P, Mohr P,
Dummer R, Trefzer U, Larkin JMG, Utikal J, Casey M, Sherman LJ,
Crist WA, Wu FS, Patel K and Schadendorf D: METRIC phase III study:
efficacy of trametinib (T), a potent and selective MEK inhibitor
(MEKi), in progression-free survival (PFS) and overall survival
(OS), compared with chemotherapy (C) in patients (pts) with BRAF
V600E/K mutant advanced or metastatic melanoma (MM). J Clin Oncol.
30(Suppl): abs. LBA8509. 2012.
|
|
61
|
Klinac D, Gray ES, Millward M and Ziman M:
Advances in personalized targeted treatment of metastatic melanoma
and non-invasive tumor monitoring. Front Oncol. 3:542013.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim KB, Lewis K, Pavlick A, Infante JR,
Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P,
Gonzalez R, Ott PA, Long G, Gardner OS, Ouellet D, Xu Y, De Marini
DJ, Le N, Patel K and Kefford R: A phase II study of the MEK1/MEK2
inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous
melanoma patients previously treated with or without a BRAF
inhibitor. International Melanoma Congress. Pigment Cell Res.
24:990–1075. 2011.
|
|
63
|
Ikenoue T, Kanai F, Hikiba Y, Obata T,
Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka
Y, Matsumura M, Kawabe T and Omata M: Functional analysis of PIK3CA
gene mutations in human colorectal cancer. Cancer Res.
65:4562–4567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Isakoff SJ, Engelman JA, Irie HY, Luo J,
Brachmann SM, Pearline RV, Cantley LC and Brugge JS: Breast
cancer-associated PIK3CA mutations are oncogenic in mammary
epithelial cells. Cancer Res. 65:10992–11000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao JJ, Liu Z, Wang L, Shin E, Loda MF
and Roberts TM: The oncogenic properties of mutant p110alpha and
p110beta phosphatidylinositol 3-kinases in human mammary epithelial
cells. Proc Natl Acad Sci USA. 102:18443–18448. 2005. View Article : Google Scholar
|
|
66
|
Janku F, Wheler JJ, Naing A, Stepanek VM,
Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA,
Moulder SL, Lee JJ, Luthra R, David SH and Kurzrock R: PIK3CA
mutations in advanced cancers: characteristics and outcomes.
Oncotarget. 3:1566–1575. 2012.PubMed/NCBI
|
|
67
|
Zhao L and Vogt PK: Class I PI3K in
oncogenic cellular transformation. Oncogene. 27:5486–5496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ligresti G, Militello L, Steelman LS,
Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA and
Libra M: PIK3CA mutations in human solid tumors. Role in
sensitivity to various therapeutic approaches. Cell Cycle.
8:1352–1358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hafsi S, Pezzino FM, Candido S, Ligresti
G, Spandidos DA, Soua Z, McCubrey JA, Travali S and Libra M: Gene
alterations in the PI3K/PTEN/AKT pathway as a mechanism of
drug-resistance. Int J Oncol. 40:639–644. 2011.PubMed/NCBI
|
|
70
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3KmTOR pathways: cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Stahl JM, Sharma A, Cheung M, Zimmerman M,
Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L and Robertson
GP: Deregulated Akt3 activity promotes development of malignant
melanoma. Cancer Res. 64:7002–7010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Meier F, Schittek B, Busch S, Garbe C,
Smalley K, Satyamoorthy K, Li G and Herlyn M: The RAS/RAF/MEK/ERK
and PI3K/AKT signaling pathways present molecular targets for the
effective treatment of advanced melanoma. Front Biosci.
10:2986–3001. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
73
|
Russo AE, Torrisi E, Bevelacqua Y,
Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and
Malaponte G: Melanoma: molecular pathogenesis and emerging target
therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
|
|
74
|
Brana I and Siu LL: Clinical development
of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
BMC Med. 10:1612012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ogita S and Lorusso P: Targeting
phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target
Oncol. 6:103–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Huang A, Fritsch C, Wilson C, Reddy A, Liu
M, Lehar J, Quadt C, Hofmann F and Schlegel R: Single agent
activity of PIK3CA inhibitor BYL719 in a broad cancer cell line
panel. Proceedings of the 103rd Annual Meeting of the American
Association for Cancer Research; Chicago, IL, Philadelphia, PA. Am
Assoc Cancer Res. abs. 3749. 2012
|
|
77
|
Jessen K, Kessler L, Kucharski J, Guo X,
Staunton J, Janes M, Elia M, Banerjee U, Lan L, Wang S, Stewart J,
Luzader A, Darjania L, Li L, Chan K, Martin M, Ren P, Rommel C and
Liu Y: A potent and selective PI3K inhibitor, INK1117, targets
human cancers harboring oncogenic PIK3CA mutations. In:
AACR-NCI-EORTC International Conference: Molecular Targets and
Cancer Therapeutics; San Francisco, CA, Philadelphia, PA. Am Assoc
Cancer Res. 10. abs. A171. 2011
|
|
78
|
Britten CD: PI3K and MEK inhibitor
combinations: examining the evidence in selected tumor types.
Cancer Chemother Pharmacol. 71:1395–1409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Markman B, Dienstmann R and Tabernero J:
Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget.
1:530–543. 2010.PubMed/NCBI
|
|
81
|
Mansh M: Ipilimumab and cancer
immunotherapy: a new hope for advanced stage melanoma. Yale J Biol
Med. 84:381–389. 2011.PubMed/NCBI
|
|
82
|
Sondak VK, Smalley KS, Kudchadkar R,
Grippon S and Kirkpatrick P: Ipilimumab. Nat Rev Drug Discov.
10:411–412. 2011. View Article : Google Scholar
|
|
83
|
Fellner C: Ipilimumab (Yervoy) prolongs
survival in advanced melanoma. Drug Forecast. 37:503–530.
2012.PubMed/NCBI
|
|
84
|
Tjin EP, Konijnenberg D, Krebbers G, Mallo
H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE,
Kroon BB, Haanen JB, Melief CJ, Vyth-Dreese FA and Luiten RM: T
cell immune function in tumor, skin, and peripheral blood of
advance stage melanoma patients: implications for immunotherapy.
Clin Cancer Res. 17:5736–5747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Levings MK, Sangregorio R and Roncarolo
MG: Human cd25(+)cd4(+) t regulatory cells suppress naive and
memory T cell proliferation and can be expanded in vitro without
loss of function. J Exp Med. 193:1295–1302. 2001.
|
|
86
|
Melero I, Hervas-Stubbs S, Glennie M,
Pardoll DM and Chen L: Immunostimulatory monoclonal antibodies for
cancer therapy. Nat Rev Cancer. 7:95–106. 2007. View Article : Google Scholar
|
|
87
|
Agarwala SS: Current systemic therapy for
metastatic melanoma. Expert Rev Anticancer Ther. 9:587–595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kirkwood JM, Tarhini AA, Panelli MC,
Moschos SJ, Zarour HM, Butterfield LH and Gogas HJ: Next generation
of immunotherapy for melanoma. J Clin Oncol. 26:3445–3455. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Antony GK and Dudek AZ: Interleukin 2 in
cancer therapy. Curr Med Chem. 17:3297–3302. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chmielowski B: Ipilimumab: a
first-in-class T-cell potentiator for metastatic melanoma. J Skin
Cancer. 2013:4238292013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Hodi FS, O’Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM,
Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I,
Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos
A and Urba WJ: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:211–223. 2010.PubMed/NCBI
|
|
92
|
Robert C and Ghiringhelli F: What is the
role of cytotoxic T lymphocyte-associated antigen 4 blockade in
patients with metastatic melanoma? Oncologist. 14:848–861.
2009.PubMed/NCBI
|
|
93
|
Hwu P: Treating cancer by targeting the
immune system. N Engl J Med. 363:779–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wolchok JD, Neyns B, Linette G, Negrier S,
Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie
T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O’Day SJ and
Lebbé C: Ipilimumab monotherapy in patients with pretreated
advanced melanoma: a randomised, double-blind, multicentre, phase
2, dose-ranging study. Lancet Oncol. 11:155–164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lipson EJ and Drake CG: Ipilimumab: an
anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res.
17:6958–6962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Di Giacomo AM, Calabrò L, Danielli R,
Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D,
Miracco C, Biagioli M, Altomonte M and Maio M: Long-term survival
and immunological parameters in metastatic melanoma patients who
responded to ipilimumab 10 mg/kg within an expanded access
programme. Cancer Immunol Immunother. 62:1021–1028. 2013.PubMed/NCBI
|
|
97
|
Feng Y, Roy A, Masson E, Chen T, Humphrey
R and Weber JS: Exposure-response relationships of the efficacy and
safety of ipilimumab in patients with advanced melanoma. Clin
Cancer Res. 19:3977–3986. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Melero I, Grimaldi AM, Perez-Gracia JL and
Ascierto PA: Clinical development of immunostimulatory monoclonal
antibodies and opportunities for combination. Clin Cancer Res.
19:997–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L,
Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM,
McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D,
Kollia GD, Gupta A, Wigginton JM and Sznol M: Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Shahabi V, Whitney G, Hamid O, Schmidt H,
Chasalow SD, Alaparthy S and Jackson JR: Assessment of association
between BRAF-V600E mutation status in melanomas and clinical
response to ipilimumab. Cancer Immunol Immunother. 61:733–737.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Davar D, Tarhini AA and Kirkwood JM:
Adjuvant immunotherapy of melanoma and development of new
approaches using the neoadjuvant approach. Clin Dermatol.
31:237–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lo RS: Combinatorial therapies to overcome
B-RAF inhibitor resistance in melanomas. Pharmacogenomics.
13:125–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Infante JR, Falchook GS, Lawrence DP,
Weber JS, Kefford RF, Bendell JC, Kurzrock R, Shapiro G, Kudchadkar
RR, Long GV, Burris HA, Kim KB, Clements A, Peng S, Yi B, Allred
AJ, Ouellet D, Patel K, Lebowitz PF and Flaherty KT: Phase I/II
study to assess safety, pharmacokinetics, and efficacy of the oral
MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the
oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol. 29(Suppl):
abs. CRA8503. 2011.
|
|
104
|
Weber JS, Flaherty KT, Infante JR,
Falchook GS, Kefford R, Daud A, Hamid O, Gonzalez R, Kudchadkar RR,
Lawrence DP, Burris HA, Long GV, Algazi AP, Lewis KD, Kim KB,
Puzanov I, Sun P, Little SM, Patel K and Sosman JA: Updated safety
and efficacy results from a phase I/II study of the oral BRAF
inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2
inhibitor trametinib (GSK1120212) in patients with BRAFi-naïve
metastatic melanoma. J Clin Oncol. 30(Suppl): abs. 8510. 2012.
|
|
105
|
Curti BD and Urba WJ: Integrating new
therapies in the treatment of advanced melanoma. PhD Current
Treatment Options in Oncology. Skin Cancer. 13:327–339.
2012.PubMed/NCBI
|
|
106
|
Ascierto PA, Simeone E, Giannarelli D,
Grimaldi AM, Romano A and Mozzillo N: Sequencing of BRAF inhibitors
and ipilimumab in patients with metastatic melanoma: a possible
algorithm for clinical use. J Transl Med. 10:1072012. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Comin-Anduix B, Chodon T, Sazegar H,
Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya
RC and Ribas A: The oncogenic BRAF kinase inhibitor PLX4032/RG7204
does not affect the viability or function of human lymphocytes
across a wide range of concentrations. Clin Cancer Res.
16:6040–6048. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wargo JA, Cogdill A, Dang P, Gupta R,
Piris A, Boni A, Garber HR, Ott H, Newton LP, Flaherty KT, Lawrence
DP, Tsao H and Fisher DE: Treatment with a selective inhibitor of
BRAFV600E increases melanocyte antigen expression and CD8 T cell
infiltrate in tumors of patients with metastatic melanoma. Cancer
Res. 71:abs. 95. 2011. View Article : Google Scholar
|
|
109
|
Wilmott JS, Long GV, Howle JR, Haydu LE,
Sharma RN, Thompson JF, Kefford RF, Hersey P and Scolyer RA:
Selective BRAF inhibitors induce marked T-cell infiltration into
human metastatic melanoma. Clin Cancer Res. 18:1386–1394. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Mijatovic S, Maksimovic-Ivanica D, Mojic
M, Malaponte G, Libra M, Cardile V, Miljkovic D, Harhaji L,
Dabideen D, Cheng KF, Bevelacqua Y, Donia M, Garotta G, Al-Abed Y,
Stosic-Grujicic S and Nicoletti F: Novel nitric oxide-donating
compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric
oxide (GIT-27NO) induces p53 mediated apoptosis in human A375
melanoma cells. Nitric Oxide. 19:177–183. 2008. View Article : Google Scholar
|
|
111
|
Donia M, Mangano K, Fagone P, De Pasquale
R, Dinotta F, Coco M, Padron J, Al-Abed Y, Lombardo GA,
Maksimovic-Ivanic D, Mijatovic S, Zocca M, Perciavalle V,
Stosic-Grujicic S and Nicoletti F: Unique antineoplastic profile of
Saquinavir-NO, a novel NO-derivative of the protease inhibitor
Saquinavir, on the in vitro and in vivo tumor
formation of A375 human melanoma cells. Oncol Rep. 28:682–688.
2012.PubMed/NCBI
|
